FDA approves new pertuzumab biosimilar - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves new pertuzumab biosimilar

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

  • 1

    The FDA approved Biocon’s pertuzumab-qcay (Pebrilzo), a biosimilar to pertuzumab (Perjeta), for adults with HER2-positive breast cancer.

  • 2

    Approved uses include metastatic treatment with trastuzumab and docetaxel, neoadjuvant treatment with trastuzumab and chemotherapy, and adjuvant treatment for patients at high risk of recurrence.

  • 3

    Biocon reported that approval was supported by structural, functional, analytical, and comparative pharmacokinetic data showing high similarity to reference pertuzumab.

  • 4

    The earliest licensed US launch date for pertuzumab-qcay is the third quarter of 2028.

  • 5

    The accompanying safety information includes boxed warnings for left ventricular dysfunction and embryo-fetal toxicity, and lists diarrhea, alopecia, neutropenia, nausea, fatigue, and peripheral neuro

Original Source(s)

Related Content